Org

aniz

ed b

y IM

K In

stitu

te fo

r med

icin

e an

d co

mm

unic

atio

n Lt

d©

BER

NEX

PO G

RO

UPE

Program

Joint Annual Meeting 2020Swiss Headache Society SHSSwiss Pain Society SPS

October 01-02, 2020 BernExposhs-sps2020.congress-imk.ch

Member of the

First Announcement

Org

aniz

ed b

y IM

K In

stitu

te fo

r med

icin

e an

d co

mm

unic

atio

n Lt

dHeadache-Symposium 2021

November 25, 2021 | 14:00-18:00Inselspital Bern, Auditorium Rossi

www.headache.ch

IMSKSY2111_First_Announcement_02.indd 1IMSKSY2111_First_Announcement_02.indd 1 09.09.20 11:3109.09.20 11:31

3

Contents

Welcome 4

Protection Concept 5

General Information 6-8

Travel Information 9

Partner Companies 10-11

Scientific Program

Thursday, October 01, 2020 12-14

Friday, October 02, 2020 15-17

Posters 18-19

List of Invited Speakers and Chairs 20-21

List of Exhibitors 22

Exhibition Plan & Hall Overview 23

4

Wel

com

e Welcome

Dear friends and colleagues

Welcome to the Annual Congress of the Swiss Headache Society and the Swiss Pain Society (formerly SGSS/SSED) on 1 and 2 October 2020 in Bern, our joint anniversary conference. This year is a special year for both societies as we are celebrating 25 years of SHS and 30 years of SPS.

The program has been designed to be correspondingly varied. The various aspects of interdisciplinary and multimodal pain therapy will be discussed, this year with the main focus on headaches. The varied program includes not only the tried and tested or controversial topics, but also the latest developments in therapy. The program is also aimed not only at headache and pain specialists, but also at younger (and older) colleagues from a wide range of medical fields, from primary care to specialists. Finally, our pro-fessional societies are multi-professional and include all health care professions dedicated to the care of (headache) pain patients.

With the “solemn” My most tricky case we want to take a look at the past of our former presidents. With the Hot Topic Lectures we offer a new presentation platform, which also allows to present short, scientific ideas or burning issues to a large audience. Besides our keynote lectures on Thursday (Peter Goadsby on headache pathophysiology and Nouchine Hadjikhani on the progress of imaging) and like the anthropolo-gist Jeremy Narby on Friday, all facets of currently useful therapies are discussed, from complementary to surgical, from medicinal to psychotherapeutic.

With this anniversary congress, we would like to stimulate the discussions in the subject areas, contribute to the concept formation of each individual and thereby improve patient care.

On behalf of the members of the scientific committee and the undersigned presidents, we are therefore very pleased to welcome you on these days.

PD Andreas Gantenbein, MD PD Konrad Maurer, MD President SHS President SPS

5

Protection Concept

Protection Concept

The health and safety of our participants, speakers, exhibitors and collaborators is paramount to us. In close cooperation with BernExpo, IMK Ltd. has drawn up a protection concept based on the regulations published by the Federal Office of Public Health (FOPH) and will ensure that the measures mentioned in the protection concept are implemented.

All measures are designed to optimally protect participants, speakers and exhibitors as well as the team of IMK Ltd. and BernExpo from an infection by the new coronavirus.

Please install the official SwissCovid app from the App store or Google Play Store on your Smartphone.

All participants are required to register in advance for the con-gress. Registrations at the venue via the congress secretariat are not possible.

The wearing of a mask is compulsory, the only zone of exclusion is the catering area. Masks (one per person and per day) as well as hand sanitizer will be distributed to all participants present.

Furthermore, the social distancing measures given by the Federal Office of Public Health (FOPH) are to be followed in the best way possible.

Keep your distance

Install the “Swiss-Covid” contact

tracing app

Register for the congress in

advance

300 people max. per room

300Compulsory wearing of

a mask

Regularly wash hands

Cough or sneeze into a tissue or into

the elbow bend

Avoid shaking hands

Current protection concept:shs-sps2020.congress-imk.ch

6

Gene

ral General Information

Date

Venue

Website

Language

Presidents

Scientific Committee

Website and Contact of the Societies

Professional Congress Organizer (PCO)

October 01-02, 2020

BERNEXPOMingerstrasse 6 | CH-3000 Bern 22www.bernexpo.ch

shs-sps2020.congress-imk.ch

The offcial congress language is English

Swiss Headache Society SHS: PD Andreas Gantenbein, MDSwiss Pain Society SPS: PD Konrad Maurer, MD

Swiss Headache Society SHSEthan Taub, MD, Basel, CHPeter Myers, MD, Geneva, CHPD Andreas Gantenbein, MD, Bad Zurzach, CH

Swiss Pain Society SPSPD Marc Suter, MD, Lausanne, CHPD Konrad Maurer, MD, Zurich, CH

Swiss Headache Society SHSwww.headache.ch | kopfweh@imk.ch

The society celebrates its 25th anniversary this year. Welcome to the anniversary year 2020

Swiss Pain Society SPSwww.swisspainsociety.ch | info@swisspainsociety.ch

The society celebrates its 30th anniversary this year. Welcome to the anniversary year 2020

IMK Institute for medicine and communication Ltd.Harald F. GrossmannMünsterberg 1 | CH-4001 BaselTel. +41 61 561 53 53www.imk.ch | congress@imk.ch

7

General

General Information

Credits

Registration FeesFees in CHF

Cancellation Policy

Confirmation of Participation

Opening Hours Secretariat

Opening Hours Industrial Exhibition

IMK must be informed about cancellations in written form.

Cancellations received up to August 31, 2020: 50% refundCancellations received starting from September 01, 2020: no refund

Attendants will receive an electronic confirmation of participation per e-mail after the congress.

Thursday, October 01, 2020 08:00-18:15hFriday, October 02, 2020 08:00-16:00h

Thursday, October 01, 2020 08:15-18:30hFriday, October 02, 2020 08:15-16:00h

Early Bird until31.08.2020

From01.09.2020

1 day 2 days 1 day 2 days

Member physician SHS | SPS 100 150 150 200

Non-member physician 150 200 200 250

Resident, Physiotherapist 70 100 120 150

Student 30* 60* 30* 60*

*All free of charge in case the student submits a poster

01.10.2020 02.10.2020

Swiss Neurological Society 7 6

Swiss Pain Society 7 7

Swiss Society for Anaesthesiology and Resuscitation 8 8

Swiss Society of General Internal Medicine 5 5

Swiss Society for Interventional Pain Management 5 5

Swiss Society for Rheumatology 7 6

8

Gene

ral

Information for Speakers

Oral Presentations Best Posters Presentations

Hot Topics Presentations

Posters

Posterviewing

Award

Award Ceremony

The lecture halls are equipped with laptop and beamer. We ask the speakers to save their presentation on a USB memory stick and take it directly to the respective lecture hall as soon as possible but the latest during the last break before the session.

In order to keep to the schedule, presenters are asked to keep to the allotted speaking time (5min. + 1min. discussion) and avoid gaps between speeches. Please refer to the scientific program for the detailed schedule.

Format A0 portrait: 118.9cm x 84.1cm Poster mounting: Thursday, October 01, 2020, 09:00-11:15hPoster boards and material/poster strips to hang up your poster will be at your disposal.

Thursday, October 01, 2020, 12:15-13:00h The presenting author is asked to be present at his poster during the official posterviewing time.

SHS | SPS Best Poster Prize

Thursday, October 01, 2020, 18:15h, room “Congress 1”

General Information

9

General

kontakt

BERNEXPO AGMingerstrasse 6, 3000 Bern 22Tel. +41 31 340 11 11Fax +41 31 340 11 10 info@bernexpo.ch

sitUationspLan

kontakt

BERNEXPO AGMingerstrasse 6, 3000 Bern 22Tel. +41 31 340 11 11Fax +41 31 340 11 10 info@bernexpo.ch

sitUationspLan

By Public TransportYou can reach the BERNEXPO site by tram, bus or S-Bahn suburban railway within a few minutes from Bern central station.

• Tram No. 9 from Bern central station to “Guisanplatz Expo” stop• S-Bahn (S1, S2, S3, S4, S31 or S44) to “Bern Wankdorf” stop, then tram No. 9 to “Wankdorf Center” stop• Bus No. 20 to “Wankdorf Bahnhof” stop, then tram No. 9 to “Wankdorf Center” stop

By CarThe BERNEXPO site is located just a few hundred metres from the Wankdorf motorway interchange. Exit the motorway and follow the signs for “BERNEXPO/expo”.

ParkingThe Expo Parking car park is available within the immediate vicinity of the event venue. On and adjacent to the venue you will find additional open-air parking spaces. Pay your parking fees with SEPP: the parking meter app works with iOS and Android, and can be downloaded for free from the App Store or Google Play.

By PlaneThe BERNEXPO site enjoys excellent transport connections to the regional Bern-Belp Airport and to the international airports in Zurich and Geneva.

• Bern-Belp Airport: transfer by car in approx. 15 minutes, by train in 35 minutes• Zurich Airport: transfer by car in approx. 90 minutes, by train in 80 minutes• Basel-EuroAirport is located near the borders of Switzerland, France and Germany.

Transfer by train in around 1 hour• Geneva-Cointrin Airport: transfer by car in 120 minutes, by train in 110 minutes

Travel Information

10

Partn

er c

ompa

nies

Joint Annual Meeting SHS | SPS - Partner Companies

Premium Partner 2020

Partner 2020

We would like to thank the following companies for supporting the Joint Annual Meeting 2020.

11

Partner companies

Partner Companies SHS

Partner Companies SPS

SHS Premium Partner 2020

SPS Partner 2020

SHS Supporter 2020

We would like to thank the following companies for supporting the Swiss Headache Society.

We would like to thank the following companies for supporting the Swiss Pain Society.

12

Thur

sday

Daily Overview | Thursday, October 01, 2020

Congress 1 Congress 4

09:00-09:15Introduction

09:15-10:45Headache

10:45-11:15 Coffee Break

11:15-12:15 Most Tricky Cases

12:15-13:00 Lunch and Poster Visit

13:00-13:45 Satellite Symposium organized by Novartis

13:00-13:45 Satellite Symposium organized by Sanofi

14:00-15:30Pathophysiology

15:30-16:00 Coffee Break

16:00-17:00Abstract Presentations

17:15-18:15 General Assembly SHS

17:15-18:15 General Assembly SPS

18:15 Award Ceremony

Joint Session Satellite Symposium

Swiss Headache Society SHS Swiss Pain Society SPS

13

Thursday

Program | Thursday, October 01, 2020

09:00-09:15 Congress 1

IntroductionAndreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

09:15-10:45 Congress 1

HeadacheChair: Andreas Gantenbein, Bad Zurzach, CH

09:15-09:45 A Clinical Approach to Episodic HeadacheAndreas Kleinschmidt, Geneva, CH

09:45-10:15 Cluster HeadacheHeiko Pohl, Zurich, CH

10:15-10:45 Hormone and Migraine, or Sex and MigraineGabriele Susanne Merki-Feld, Zurich, CH

10:45-11:15 Coffee Break

11:15-12:15 Congress 1

Most Tricky CasesChair: Andreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

12:15-13:00 Lunch and Poster Visit

13:00-13:45 Congress 1

Satellite Symposium organized by Innovative Approach in Migraine to Enhance Efficiency and EffectivenessChair: Andreas Gantenbein, Bad Zurzach, CH

Heiko Pohl, Zurich, CH

Andreas Gantenbein, Bad Zurzach, CH

13:00-13:45 Congress 4

Satellite Symposium organized by Metamizol - induzierte Neutropenie /Agranulozytose

Ulrike Stamer, Bern, CH

14:00-15:30 Congress 1

PathophysiologyChair: Marc Suter, Lausanne, CH

14:00-14:45 PathophysiologyPeter Goadsby, London, UK

14:45-15:30 Imaging Pathophysiology Nouchine Hadjikhani, Boston, US

15:30-16:00 Coffee Break

14

Thur

sday

Program | Thursday, October 01, 2020

16:00-17:00 Congress 1

Abstract PresentationsChairs: Peter Myers, Geneva | Marc Suter, Lausanne

16:00-16:06 HT01 | Intraoperative CT (AIRO®) navigation as a new tool in percutaneous retrogasserian alcohol rhizolysis for trigeminal neuralgiaL Bertulli, M Dalolio, P Maino, D Kuhlen, L Valci | Lugano, CH

16:06-16:12 HT02 | Brainspotting, shaking and tapping: new approaches to the unholy trinity “trauma, anxiety and chronic pain”H Nibel, A Herold, Zurich, CH

16:12-16:18 O01 | Psychosocial resources and chronic pain in individuals with spinal cord injury: evidence from the second Swiss national community surveyC Braunwalder, Bern, CH

16:18-16:24 P01 | The role of endogenous opioids in mediating the pleasant feeling of pain relief in humansL Sirucek, R Price, W Gandhi, M Hoeppli, E Fahey, A Qu, S Becker, P Schweinhardt | Zurich, CH; Montreal, CA; Reading, GB

16:24-16:30 P02 | Comprehensiveness and Validity of Multidimensional Assessment in Patients with Chronic Low Back PainT Benz, S Lehmann, A Elfering, P Sandor, F Angst | Bad Zurzach, CH; Bern, CH

16:30-16:36 P03 | Pain trajectories based on routine pain scores predict chronic postopera-tive pain by early pain intensity, but not by the slope of pain resolutionS Grosse, A Bourezg, S Mathivon, B Rehberg-Klug | Geneva, CH

16:36-16:42 P04 | Detection of Social Problems in Chronic Pain Patients Using a New QuestionnaireA Ljutow, J Krebs, K Schwerzmann, P Huber | Nottwil, CH

16:42-16:48 P05 | Fear avoidance beliefs limit lumbar spine flexion during object lifting in pain-free adults – A protective strategy with negative consequences?D Knechtle, S Stefan, M Suter, P Schweinhardt, M Meier | Zurich, CH Bern, CH

16:48-16:54 P06 | Imaging Neurovascular Uncoupling In Acute Migraine With Aura With Susceptibility Weighted ImagingF Kellner-Weldon, M Jossen, PS Breiding, L Grunder, C Schankin, A Scutelnic, U Fischer, R Muri, M Pastore-Wapp, R Wiest, R Wiest, M El-Koussy | Luzern, CH; Bern, CH

16:54-17:00 P07 | Extended overview of the longitudinal pain-depression association: a comparison of 6 naturalistic cohort studies of specific chronic pain conditionsT Benz, F Angst, S Lehmann, S Wagner, B Simmen, P Sandor, M Gengenbacher, J Angst | Bad Zurzach, CH; Zurich, CH

17:15-18:15 Congress 1

General Assembly SHS

17:15-18:15 Congress 4

General Assembly SPS

18:15 Congress 1

Award Ceremony

15

Friday

Daily Overview | Friday, October 02, 2020

Congress 1

08:30-09:30Pain in the Head and Neck: The Neurosurgeon’s Contribution

09:30-10:00 Coffee Break

10:00-10:30 Satellite Symposium organized by Teva Pharma

10:30-12:15 Pain Treatment and Controversy Around the World

12:15-13:00 Satellite Symposium organized by Eli Lilly

12:15-13:00 Lunch

13:15-14:15Psychological Aspects of Pain

14:15-14:45 Coffee Break

14:45-15:45Integrative Medicine

15:45-16:00Closing Remarks

Joint Session Satellite Symposium

16

Frid

ay

Program | Friday, October 02, 2020

08:30-09:30 Congress 1

Pain in the Head and Neck: The Neurosurgeon’s ContributionChair: Catherine Dozier, Carouge, CH | Ethan Taub, Basel, CH

08:30-09:00 Neuromodulation for Chronic HeadacheJocelyne Bloch, Lausanne, CH

09:00-09:30 The Cervical Spine and Pain in the Head and in the NeckGregory Jost, Biel, CH

09:30-10:00 Coffee Break

10:00-10:30 Congress 1

Satellite Symposium organized by Is Blocking the CGRP System Safe?Chair: Andreas Gantenbein, Bad Zurzach, CH

Karl Messlinger, Erlangen-Nürnberg, DE

10:30-12:15 Congress 1

Pain Treatment and Controversy Around the WorldChairs: Marie Besson, Geneva, CH | Peter Myers, Geneva, CH

10:30-11:15 The Psychedelic Plant TeachersJeremy Narby, Porrentruy, CH

11:15-11:45 Pain Treatment - Opioids Marc Suter, Lausanne, CH

11:45-12:15 Cannabinoids and HeadacheClaude Vaney, Tschugg, CH

12:15-13:00 Lunch

12:15-13:00 Congress 1

Satellite Symposium organized by

Predict, Prevent, Conquer: Beyond Head Pain

Multidisciplinary Management of Migraine and Health-Related Quality of Life in Patients Receiving Galcanezumab

17

Friday

Program | Friday, October 02, 2020

13:15-14:15 Congress 1

Psychological Aspects of PainChair: Beat Steiger, Zurich, CH

13:15-13:45 Soma vs. Psyche, Pain Concepts and Diagnoses Over TimePaul Nilges, Mainz, DE

13:45-14:15 Pain Psychological Therapy: Which Procedures Are Effective?Ursula Galli, Zurich, CH | Julia Kaufmann, Nottwil, CH | Beat Steiger, Zurich, CH

14:15-14:45 Coffee Break

14:45-15:45 Congress 1

Integrative MedicineChair: Noemì Zurròn, Bulle, CH

14:45-15:15 HypnosisPeter Sandor, Baden, CH

15:15-15:45 Acupuncture and Placebo in Headache Therapy Konrad Streitberger, Bern, CH

15:45-16:00 Congress 1

Closing RemarksAndreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

18

Post

ers

Posters

P01

P02

P03

P04

P05

P06

P07

P08

P09

P10

P11

The role of endogenous opioids in mediating the pleasant feeling of pain relief in humans L Sirucek, R Price, W Gandhi, M Hoeppli, E Fahey, A Qu, S Becker, P Schweinhardt | Zurich, CH; Montreal, CA; Reading, GB

Comprehensiveness and Validity of Multidimensional Assessment in Patients with Chronic Low Back PainT Benz, S Lehmann, A Elfering, P Sandor, F Angst | Bad Zurzach, CH; Bern, CH

Pain trajectories based on routine pain scores predict chronic postoperative pain by early pain intensity, but not by the slope of pain resolutionS Grosse, A Bourezg, S Mathivon, B Rehberg-Klug | Geneva, CH

Detection of Social Problems in Chronic Pain Patients Using a New QuestionnaireA Ljutow, J Krebs, K Schwerzmann, P Huber | Nottwil, CH

Fear avoidance beliefs limit lumbar spine flexion during object lifting in pain-free adults – A protective strategy with negative consequences?D Knechtle, S Stefan, M Suter, P Schweinhardt, M Meier | Zurich, CH; Bern, CH

Imaging Neurovascular Uncoupling In Acute Migraine With Aura With Susceptibility Weighted ImagingF Kellner-Weldon, M Jossen, PS Breiding, L Grunder, C Schankin, A Scutelnic, U Fischer, R Muri, M Pastore-Wapp, R Wiest, R Wiest, M El-Koussy | Luzern, CH; Bern, CH

Extended overview of the longitudinal pain-depression association: a comparison of 6 naturalistic cohort studies of specific chronic pain conditionsT Benz, F Angst, S Lehmann, S Wagner, B Simmen, P Sandor, M Gengenbacher, J Angst | Bad Zurzach, CH;1 Zurich, CH

Role of Intravenous Ketamine in Aborting Cluster Headaches: A Retrospective StudyL Granata, L Sakellaris | Zürich, CH; St.Gallen, CH

Understanding and restoring dopaminergic function in Fibromyalgia patients using a mindfulness-based psychological intervention: A 18F-DOPA PET-studyM Burckhardt, K Ledermann, C Berna Renella, J N. Chabwine, J Jenewein, V Treyer, H Sprott, P Schweinhardt, R von Känel, C Martin Sölch | Fribourg, CH; Lausanne, CH; Zurich, CH

Reliable Elicitation of the Nociceptive Withdrawal Reflex in Human ParticipantsA Guekos, A Grata, G Sharvit, M Schubert, M Hubli, P Schweinhardt | Zurich, CH; Geneva, CH

Treatment of Neuropathic Pain After Brachial Plexus Injury by Body Schema Reorganization - Case Report of a New Therapeutic ApproachC Junker-Tschopp, A Ljutow, E Palardy, K Ottiger-Böttger | Geneva, CH; Nottwil, CH

The poster presentations can be found on the following page of the programme:

P01-P07 Abstract Presentations: Page 14

19

Posters

Posters

P12

P13

P14

P15

P16

P17

P18

P19

The interplay between anxiety, insomnia and the affective component of pain (and its GAB-Aergic EEG counterpart) discloses a preliminary mechanistic model of fibromyalgiaL Mory, D De Oliveira F., C Mancini, CA Wicht, M Mouthon, J N. Chabwine | Fribourg, CH

Galcanezumab in patients with treatment-resistant migraine: results from the open-label phase of the CONQUER Phase 3 trialHC Detke, U Reuter, C Lucas, D Dolezil, A Hand, A Tockhorn-Heidenreich, C Stroud, SK Aurora, SD Broicher | Indianapolis, US; Berlin, DE; Lille, FR; Prague, CZ; Durham, US; Vernier, CH

Changes in work productivity and interictal burden: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)D Garcia-Azorin, J Ford, DC Buse, A Hand, L Wietecha, H Detke, SD Broicher | Valladolid, ES; Indianapolis, US; Bronx, US; Durham, US; Vernier, CH

Somatosensory profiling of patients undergoing alcohol detox: Do neuropathic pain and sensory loss represent a problem?A Fernandez, G Graf, J Daeppen, C Berna Renella, M Suter | Lausanne, CH

Impact of galcanezumab on total pain burden: findings from Phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraineJ Ailani, JS Andrews, M Rettiganti, R Nicholson, SD Broicher | Washington DC, US; Indianapolis, US; Vernier, CH

Shake if off: a new approach to chronic pain and other chronic health issuesH Nibel | Zürich, CH

Does inappropriate behavior hurt or stink? The interplay between neural representations of somatic experiences and moral decisionsG Sharvit, E Lin, P Vuilleumier, C Corradi-Dell’Acqua | Zurich, CH; Geneva, CH

Leg pain with sensory positive signs: Is this nociplastic pain? A case reportM Ernst, A Ljutow, L Stockinger, G Landmann | Nottwil, CH

20

Spea

kers

| Ch

airs

BPD Marie Besson, MDHôpitaux Universitaires GenèveCentre multidisciplinaire de la douleurRue Gabrielle-Perret-Gentil 4CH-1205 Geneva

PD Prof. Jocelyne Bloch, MDCentre Hospitalier Universitaire VaudoisNeurochirugieRue du Bugnon 46CH-1011 Lausanne

DCatherine Dozier, MD15, Place du TempleCH-1227 Carouge

GUrsula Galli, PhDUniversitätsspital Zürich/ Universität ZürichPsychotherapeutisches ZentrumAttenhoferstrasse 9CH-8032 Zurich

PD Andreas R. Gantenbein, MDRehaClinic Bad ZurzachQuellenstrasse 34CH-5330 Bad Zurzach Prof. Peter Goadsby, MBBS MD PhD DSc FRACP FRCPKings College LondonBasic and Clinical NeuroscienceStrandUK-WC2R 2LS London

Adresses of Invited Speakers and Chairs

JPD Gregory Jost, MDSpitalzentrum BielSpinale ChirurgieVogelsang 84CH-2501 Biel

Julia Kaufmann, MScSchweizer Paraplegiker-ZentrumSchmerzpsychotherapieGuido A. Zäch-Strasse 1CH-6207 Nottwil

KProf. Andreas Kleinschmidt, MDHôpitaux Universitaires GenèveService de Neurologie4, Rue Gabrielle Perret-GentilCH-1211 Geneva 14

MPD Konrad Maurer, MDInstitut für Interventionelle Schmerzmedizin Zürich AGPfingstweidstr. 60 BCH-8005 Zurich Prof. Gabriele Merki-Feld, MDUniversitätsspital ZürichKlinik für Reproduktions-EndokrinologieDepartement FrauenheilkundeFrauenklinikstrasse 10CH-8091 Zurich Peter Myers, MDCabinet medicalNeuorologieRuelle du Couchant 7CH-1207 Geneva

21

Speakers | Chairs

Adresses of Invited Speakers and Chairs

NJeremy Narby, MDNouvelle PlanèteRoute de Courgenay 28CH-2900 Porrentruy Paul Nilges, PhDDRK-SchmerzzentrumAuf der Steig 14DE-55131 Mainz Prof. Hadjikhani Nouchine, MD Mass General HospitalMartinos Center for Biomedical Imaging149, 13th StreetUS-02129 Boston, MA

PHeiko Pohl, MDUniversitätsspital Zürich/Universität ZürichNeurologieFrauenklinikstrasse 26CH-8091 Zurich SProf. Peter Sandor, MDReha Clinic ZurzachNeurologieQuellenstrasse 24CH-5330 Bad Zurzach Beat Steiger, lic. phil.Universität ZürichZentrum für ZahnmedizinPlattenstrasse 11CH-8032 Zurich

Konrad Streitberger, MDInselspital BernKlinik für Anästhesiologie und SchmerztherapieFreiburgstrasseCH-3010 Bern

PD Marc Suter, MDCentre hospitalier universitaire VaudoisService d’anesthésiologieRue du Bugnon 46CH-1011 Lausanne

TEthan Taub, MDUniversitätsspital BaselNeurochirurgieSpitalstrasse 21CH-4031 Basel VClaude Vaney, MDKlinik BethesdaNeurorehabilitationCH-3233 Tschugg

ZNoemì Zurròn, MDCentre hospitalier universitaire VaudoisCentre d’Antalgie / CemicRue du Bugnon 46CH-1011 Lausanne

22

Exhi

bitio

n

List of Exhibitors

5691214372810

1234567891012

Alfasigma Schweiz AGAlmirall AGEli Lilly Suisse SAElosan AGGrünenthal Pharma AGMedtronic (Schweiz) AGNeurolite AGNovartis Pharma Schweiz AGPfizer PFE Switzerland GmbHSanofi-aventis (schweiz) agTeva Pharma AG

Grünenthal Pharma AGPfizer PFE Switzerland GmbHNeurolite AGMedtronic (Schweiz) AGAlfasigma Schweiz AGAlmirall AGNovartis Pharma Schweiz AGSanofi-aventis (schweiz) agEli Lilly Suisse SATeva Pharma AGElosan AG

Alphabetical Order By Booth NumberNo NoCompany Company

Opening Hours of the Industrial Exhibition:Thursday, October 01, 2020 08:15-18:30Friday, October 02, 2020 08:15-16:00

Congress3

Congress6 Congress

7Congress

8

Congress5

Plenary RoomCongress

1

Parallel RoomCongress

4

23

Exhibition & Hall Overview

Elevator

Mai

n En

tranc

e(D

owns

tairs

)

Congress6-8

Wardrobe

PosterExhibiton

Exhibition Plan & Hall Overview

Floor 1

Floor 2

10 12SIG/SPS

4 35

1

26

8 97Se

cret

aria

t

* In einer Interimsanalyse einer offenarmigen Extension bei Patienten mit episodischer Migräne waren 32,9 % nach 4,5 Jahren migränefrei (sekundärer Endpunkt). Die Patienten erhielten zunächst 70 mg Aimovig® monatlich (N = 383) und wurden nach einer mittleren Behandlungsdauer von 2 Jahren auf 140 mg Aimovig® (n = 250) gesteigert (4,2 % Studienabbrüche aufgrund unerwünschter Ereignisse, 3,1 % Studienabbrüche aufgrund unzureichender Wirksamkeit). Von den 250 Patienten hatten zum Zeitpunkt der Interimsanalyse 221 (88 %) die Extension beendet oder waren noch in der Studie. Für die Wirksamkeitsanalyse nach 4,5 Jahren standen Daten von 149 Patienten zur Verfügung. ** Aimovig® ist ein vollständig humaner monoklonaler Antikörper.3 *** Aimovig® ist in 2 Dosierungen erhältlich (70 mg und 140 mg Fertigpens). # Aimovig® reduzierte die Anzahl der monatlichen Migränetage und erhöhte die Lebensqualität im Vergleich zur Baseline jeweils signifi kant gegenüber Placebo.1,2,4,5 ## Einmal monatliche Selbstapplikation, individuell auf den Patienten angepasste Dosierung (Initialdosis 70 mg, Steigerung auf 140 mg bei ungenügender Wirkung möglich)3

Referenzen: 1. Dodick DW et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38(6):1026–1037. 2. Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377(22):2123–2132. 3. Aimovig® Fachinformation. Stand Mai 2019. www.swissmedicinfo.ch. 4. Lipton et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology 2019;92(19):e2250–e2260. 5. Tepper S et al. Safety and effi cacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16(6): 425–434. 6. Ashina M et al. Sustained effi cacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period. Präsentation IHC-OR-039 auf dem 19. Kongress der International Headache Society, 5.–8. September 2019, Dublin, Ireland. 7. Dammerman R und Mead J. User Acceptance of a Prefi lled Auto-injector Device for Erenumab in Patients with Migraine. Poster IHC-LB-032 präsentiert auf dem 19. Kongress der International Headache Society, 5.–8. September 2019, Dublin, Ireland.

Aimovig® Z: Injektionslösung zur subkutanen Anwendung (Fertigspritze und Fertigpen). 1 Fertigspritze bzw. 1 Fertigpen zu 1mL enthält 70 mg oder 140 mg Erenumab. I: Prophylaktische Behandlung der Migräne bei Erwachsenen, sofern diese indiziert ist. D: Empfohlen wird eine Aimovig-Dosis von 70 mg als subkutane Injektion einmal monatlich. Bei Patienten, die auf diese Dosierung eine ungenügende Wirkung zeigen, kann die Dosierung auf 140 mg einmal monatlich gesteigert werden, solange dadurch eine bessere Wirkung nachweisbar ist. Detaillierte Anweisung und spezielle Patientengruppen s. www.swissmedicinfo.ch. KI: Überempfi ndlichkeit gegenüber dem Wirkstoff Erenumab oder einem der Hilfsstoffe gemäss Zusammensetzung. VM: Die abnehmbare Kappe enthält trockenen Naturkautschuklatex, der allergische Reaktionen hervorrufen kann. Die Sicherheit und Wirksamkeit von Aimovig bei Kindern und Jugendlichen ist nicht untersucht worden. Während Schwangerschaft und Stillzeit sollte Aimovig nicht angewendet werden, es sei denn dies ist eindeutig erforderlich. Einzelheiten s. www.swissmedicinfo.ch. IA: Aimovig zeigte keinen Einfl uss auf die Pharmakokinetik von Sumatriptan, sowie eines oralen Kombinationspräparats zur Empfängnisverhütung, das Ethinylestradiol und Norgestimat enthielt. Erenumab wird nicht von Cytochrom P450 Enzymen metabolisiert, daher sind Interaktionen mit Substraten, Induktoren oder Inhibitoren von Cytochrom P450-Enzymen unwahrscheinlich. Einzelheiten s. www.swissmedicinfo.ch. UW: Häufi g: Obstipation, Juckreiz, Muskelkrämpfe, Reaktionen an der Injektionsstelle (Schmerzen, Erythem oder Juckreiz). Einzelheiten s. www.swissmedicinfo.ch. P: Injektionslösung in einer Fertigspritze: 1 Fertigspritze zu 70 mg oder 140 mg: Injektionslösung im Fertigpen: 1 Fertigpen zu 70 mg oder 140 mg: Verkaufskategorie: B. Weitere Informationen fi nden Sie unter www.swissmedicinfo.ch. V02 Mai 2019.

Novartis Pharma Schweiz AG, Risch; Adresse: Suurstoffi 14, 6343 Rotkreuz, Tel. 041 763 71 11

NO52

787

06/2

020

Genug ist genug.Weniger Migräne,

mehr vom Leben.#,1–5

100 %MIGRÄNEFREI*Jeder 3. Patient erreicht vollständige Migränefreiheit*,6

Sicherheitsprofi l auf Placebo-Niveau,1–3

über 4 Jahre bestätigt 6

100 %HUMAN**

Flexibilität in der Dosierung, die ins Leben passt##,3,7

100 %INDIVIDUELL***

00042_Y_AIM_Anzeigenschaltung_2020_de_148x210+3_RZ_200608_FK.indd 1 08.06.20 10:52